Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · IEX Real-Time Price · USD
2.11
-0.08 (-3.65%)
At close: Sep 22, 2023, 4:00 PM
2.13
+0.02 (0.95%)
After-hours: Sep 22, 2023, 7:52 PM EDT
-3.65%
Market Cap 207.97M
Revenue (ttm) 119.25M
Net Income (ttm) -211.56M
Shares Out 98.56M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,672,661
Open 2.22
Previous Close 2.19
Day's Range 2.10 - 2.23
52-Week Range 2.10 - 23.96
Beta 1.47
Analysts Hold
Price Target 6.90 (+227.01%)
Earnings Date Nov 2, 2023

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the dev... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2013
Employees 551
Stock Exchange NASDAQ
Ticker Symbol FATE
Full Company Profile

Financial Performance

In 2022, FATE's revenue was $96.30 million, an increase of 72.44% compared to the previous year's $55.85 million. Losses were -$281.72 million, 32.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $6.9, which is an increase of 227.01% from the latest price.

Price Target
$6.9
(227.01% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Fate Therapeutics to Present at Upcoming September Investor Conferences

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

23 days ago - GlobeNewsWire

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Ch...

6 weeks ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

2 months ago - GlobeNewsWire

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) ...

3 months ago - Business Wire

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on be...

3 months ago - Business Wire

Fate Therapeutics to Present at Upcoming June Investor Conferences

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-c...

4 months ago - GlobeNewsWire

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large ...

5 months ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...

5 months ago - GlobeNewsWire

FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2...

6 months ago - Business Wire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)

NEW YORK , March 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc.. Shareholders who purchased shares of FATE during the class period l...

6 months ago - PRNewsWire

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. ("Fate" ...

6 months ago - Accesswire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investor...

6 months ago - Business Wire

FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders

NEW YORK , March 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that th...

6 months ago - PRNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023

NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on ...

6 months ago - PRNewsWire

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

NEW YORK , March 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 a...

6 months ago - PRNewsWire

FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit

BENSALEM, Pa. , March 17, 2023 /PRNewswire/ -- Law Offices of Howard G.

6 months ago - PRNewsWire

FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023

NEW YORK , March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE). To re...

6 months ago - PRNewsWire

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , March 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit. CLASS DEFIN...

6 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company")...

6 months ago - PRNewsWire

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

NEW YORK , March 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 a...

7 months ago - PRNewsWire

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK , March 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 an...

7 months ago - PRNewsWire

Fate Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...

7 months ago - GlobeNewsWire

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables

7 months ago - GlobeNewsWire

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK , Feb. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 an...

7 months ago - PRNewsWire

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK , Feb. 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 an...

7 months ago - PRNewsWire